D-0616-2017 Class II Terminated
FDA drug recall D-0616-2017 was initiated by Claris Lifesciences Inc on Mar 10, 2017 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product. The recall status is terminated (terminated Sep 18, 2020). Affected quantity: 72072 units.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 5, 2017
- Initiation Date
- Mar 10, 2017
- Termination Date
- Sep 18, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 72072 units
Product description
Metronidazole Injection, USP, 500 mg/100 mL, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-001-24
Reason for recall
Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.
Distribution pattern
Nationwide
Code information
Lot #: A060205; A060209, Exp.Jan 2018
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0616-2017
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026